Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Leahy AB, Devine KJ, Li Y, Liu H, et al. Blood 2022;139:2173-2185.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Leahy AB, Devine KJ, Li Y, Liu H, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood 2022;139:2173-2185.
PMID: 34871373